Predict your next investment

ThinkCyte company logo
ELECTRONICS | Technical & Scientific Instrumentation

See what CB Insights has to offer

Founded Year



Series B | Alive

Total Raised


Last Raised

$26M | 8 mos ago

About ThinkCyte

ThinkCyte develops Ghost Cytometry technology, a high-throughput image-based cell sorting system that integrates advanced imaging, machine learning, and microfluidics technologies. It enables researchers to identify cells based on their images and isolate target cells, including rare cells, in real-time. This approach brings throughput, analysis, and sorting on a single cell level to disciplines such as drug discovery, cell therapy, and clinical diagnostics.

ThinkCyte Headquarter Location

U. Tokyo Entrepreneur Plaza 7-3-1 Hongo, Bunkyo-ku

Tokyo, 113-0033,


Latest ThinkCyte News

Financings for May 25, 2021

May 25, 2021

Home » Financings for May 25, 2021 Financings for May 25, 2021 May 25, 2021 Duality Biologics Co. Ltd., of Princeton, N.J., and Shanghai, said it completed a $90 million series B financing led by Lilly Asia Ventures and jointly invested by Yunion Healthcare Fund, Huagai Capital, NRL Capital, Green Pine Capital Partners and Oriza Holdings. Series A investor Wuxi Biologics continued to increase its stake in the round to accelerate Dualitybio's R&D progress using its integrated technology platforms. Dualitybio has raised more than $120 million since its establishment in January 2020. Funds raised in the latest round will be used mainly for conducting preclinical research, clinical trials, and expanding pipeline through strategic in-licensing, out-licensing and research collaborations globally. G2 Bio Cos., of Philadelphia, launched with a $200 million investment commitment from Temasek to accelerate development of genetic-based therapies. The G2 Bio Cos. were founded in 2021 by University of Pennsylvania Gene Therapy Program, James Wilson, Tachi Yamada and Temasek, a global investment firm headquartered in Singapore, with the aim of funding and developing potential next-generation gene therapy candidates from the University of Pennsylvania Gene Therapy Program. Ose Immunotherapeutics SA, of Nantes, France, said it obtained public funding of €10.7 million (US$13.1 million) under the “Capacity Building” call for projects, operated on behalf of the French government by Bpifrance as part of the “Programme d’investissements d’avenir” and of the plan “France Relance,” to support further development of its program on Covepit, its multivariant vaccine against COVID-19, currently in phase I testing. Renbio Inc., of New York, said it completed a $24 million series A financing, led by Taiwan-based Ruentex Group. The company also signed a license agreement with Columbia University, giving Renbio the exclusive worldwide development and commercialization rights to a bispecific antibody (RB-100) for COVID-19 that targets two distinct sites on the spike of SARS-CoV-2. In preclinical studies, RB-100 demonstrated robust antiviral activity against SARS-CoV-2 variants that have recently emerged from the U.K. (B.1.1.7), South Africa (B.1.351), Brazil (P.1), California (B.1.427 and B.1.429) and New York (B.1.526). Under the license agreement, Columbia University received an equity stake in Renbio. Additional terms were not disclosed. Renbio intends to use proceeds from the series A to completed IND-enabling preclinical studies and initiate a phase I/II trial of RB-100 in 2021. In parallel, the company will continue the development of its DNA-based MYO (Make Your Own) Technology antibody delivery platform, with the goal of advancing a lead candidate into the clinic within two years. Thinkcyte Inc., of Tokyo, completed a $26 million series B financing, led by Sparx Group, with participation from Sysmex Corp. and Sumitomo Mitsui Trust Investment, as well as existing investors SBI Group and Itochu Technology Ventures. The company has raised a total of $45 million to date. Thinkcyte uses Ghost Cytometry technology, which involves a combination of proprietary advanced optics, microfluidics and machine-learning techniques for cell therapy, clinical diagnostics and drug discovery.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ThinkCyte

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ThinkCyte is included in 6 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

8,330 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Medical Devices

7,888 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,707 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Digital Health

12,243 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Biopharma Tech

818 items

ThinkCyte Patents

ThinkCyte has filed 6 patents.

The 3 most popular patent topics include:

  • Cell biology
  • Molecular biology
  • 3D imaging
patents chart

Application Date

Grant Date


Related Topics



Norepinephrine, Molecular biology, Cell biology, T cells, Navigational equipment


Application Date


Grant Date


Related Topics

Norepinephrine, Molecular biology, Cell biology, T cells, Navigational equipment



ThinkCyte Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ThinkCyte Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.